At a panel at the GRx+Biosims 2018, Molly Burich, MS, director of public policy for biosimilars and reimbursement at Boehringer Ingelheim, and Melissa Andel, MPP, vice president of health policy at Applied Policy, discussed the impact that US policy developments are having and will continue to have on the biosimilars market.
At a panel at the GRx+Biosims 2018, Molly Burich, MS, director of public policy for biosimilars and reimbursement at Boehringer Ingelheim (BI), and Melissa Andel, MPP, vice president of health policy at Applied Policy, discussed the impact that US policy developments are having and will continue to have on the biosimilars market.
According to Andel, CMS’ newly announced policy to allow Medicare Advantage (MA) plans to implement step therapy provides an opportunity for biosimilar uptake, especially since the popularity of MA plans continues to grow as more patients are “aging into Medicare.”
Read more about MA plans and step therapy.
On the heels of that policy overhaul, said Andel, CMS announced that, in 2020, Part D plans will be able to use indication-based formulary design, contrary to the current landscape in which plans are required to cover all FDA-approved indications for a covered drug. How this new policy will impact biosimilars is not yet clear, but Andel said that it may offer opportunities related to contracting.
Andel added that in the commercial market, aggressive rebating strategies from reference product sponsors are limiting uptake of biosimilars, so biosimilars may need “coverage plus” (which she described as coverage with a larger add-on payment for physicians) or even value-based agreements, linked with patient outcomes, in order to see better uptake.
Burich explained that, from the manufacturer’s point of view, the past year has seen a number of positive changes related to reimbursement, including CMS’ announcement of separate billing codes for biosimilars and inclusion of biosimilars in the Medicare Part D coverage gap discount program. The Trump administration is serious about lowering drug prices, said Burich, and this is among the first times that she has seen such close alignment between CMS and FDA in terms of their goals.
A key question for Burich, however, is who or what will eventually drive the biosimilar market; and payers, patients, and automatic substitution, she said, all have a role to play.
Payers, she said, have begun to take steps to help biosimilar adoption; leading pharmacy benefit managers have begun to include biosimilars on their national formularies, though they have not yet excluded reference products as a means to drive biosimilar uptake, and “I think the rebate dynamics certainly play a role.”
On the patient side, whereas individual patients have felt the benefit of generic drugs in terms of their out-of-pocket expenses, they do not yet have a true incentive to use a biosimilar. “An esoteric benefit to the system,” she explained, is no match for a direct benefit to the patient.
Interchangeability—and Burich noted that BI is the only biosimilar developer to announce a study designed expressly to demonstrate interchangeability—is also an important because it will allow for automatic substitution at the pharmacy level, which was a key driver of generic uptake. Burich said that BI generally agrees with the FDA’s current draft guidance on interchangeability, as it sets an appropriately high bar for an interchangeable product. However, the time and resource investment necessary for such a study means that interchangeability can only be a catalyst, not the only enabler, of the market.
Burich also noted that most US states now have laws in place to eventually govern substitution of interchangeable biologics, but she raised the question of whether these laws should target interchangeability or a different standard, saying “did we base substitution on the right thing? Is interchangeability going to be something that many products pursue, or maybe just certain products?” She noted that FDA Commissioner Scott Gottlieb, MD, has said that the agency is considering whether more flexibility is warranted in the interchangeability guidance.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.